Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells
Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells
复制标题
DOI：
10.1016/j.canlet.2004.01.038
复制
发表时间：
2004-07-28
期刊：
影响因子：
9.7
通讯作者：
Sasaki, K
中科院分区：
文献类型：
--
作者：
Toshimitsu, H;Hashimoto, K;Sasaki, K
为了阐明食管鳞癌顺铂耐药的分子基础，我们采用基因芯片技术。通过暴露于增加浓度的CDDP，从YES-2产生了CDDP抗性细胞系（YES-2/CDDP），与亲本YES-2 ESCC细胞系相比，该细胞系显示出对CDDP的抗性增加7.5倍，并且CDDP积累减少3倍。通过cDNA微阵列分析，我们确定了44个基因在YES-2/CDDP和YES-2细胞中的表达水平存在显著差异。有趣的是，这44个基因中有15个编码核糖体相关蛋白，几乎所有这些蛋白在YES-2/CDDP细胞中表达不足。我们目前的数据表明，许多核糖体相关基因可能参与了食管鳞癌对顺铂的获得性耐药，这些信息可能使我们更好地了解顺铂耐药的机制。(C)2004爱思唯尔爱尔兰有限公司保留所有权利。
To clarify the molecular basis of acquired cisplatin (CDDP) resistance in esophageal squamous cell carcinoma (ESCC), we used cDNA microarray technology. A CDDP-resistant cell line (YES-2/CDDP), which shows a 7.5-fold increase in resistance to CDDP and a 3-fold decrease in CDDP accumulation compared with the parental YES-2 ESCC cell line, was generated from YES-2 by exposure to increased concentrations of CDDP. By cDNA microarray analysis, we identified 44 genes with significantly different expression levels between YES-2/CDDP and YES-2 cells. Interestingly, 15 of these 44 genes encoded ribosome-related proteins, almost all of which were underexpressed in YES-2/CDDP cells. Our present data suggest that many ribosome-related genes may be involved in the acquired resistance to CDDP in ESCC and that such information may allow us to better understand the mechanism of CDDP resistance. (C) 2004 Elsevier Ireland Ltd. All rights reserved.